Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001024 · ClinicalTrials.gov registry record · NA

The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS

A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
32
Enrollment target

NCT00001024 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001024, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT. Clinical objectives: To gain insight into the degree of correlation between immunologic surrogate markers for HIV disease (e.g., CD4, beta-2 microglobulin) as compared to measures of HIV replication in PB and LT. To assess changes in PB and LT viral burden after antiretroviral therapy and to determine its ability to predict an antiviral response. One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.

Interventions

  • DRUG Zidovudine
  • DRUG Didanosine

Trial Details

FieldValue
Enrollment Target 32 participants
Est. Completion 2002-06
Phase NA

What the Registry Record Tells You About NCT00001024

The ClinicalTrials.gov registry entry for NCT00001024 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.

NCT00001024 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001024 about?

NCT00001024 is a clinical study titled "The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS". Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT. Clinical objectives: To gain insight into the degree of corr...

What is the current status of trial NCT00001024?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. Estimated completion is 2002-06.

What interventions are being tested in trial NCT00001024?

The interventions under investigation include: Zidovudine (DRUG), Didanosine (DRUG).

Who is sponsoring clinical trial NCT00001024?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.